SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type

Launched by FUZHOU GENERAL HOSPITAL · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help detect lung cancer early, specifically focusing on two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Early detection is important because it can significantly improve a patient's chances of successful treatment. The researchers are using a technique called Surface-Enhanced Raman Spectroscopy (SERS), which analyzes blood samples to find specific changes in the body that might indicate cancer. In earlier tests, this method showed promising results, correctly identifying cancer types in about 80% of cases.

To participate in this study, individuals must have been diagnosed with lung cancer and be willing to follow the study guidelines. They should not have other types of cancer, severe lung diseases, or certain other health issues. Participants will provide blood samples, which will be analyzed using the new diagnostic system. The trial aims to gather more evidence to confirm the effectiveness of this method for early lung cancer detection. If you're considering joining, you'll need to give your written consent, and the study team will ensure you understand what’s involved.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);
• • 2. Participants are willing to participate in this study and follow the research plan;
• • 3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;.
• Exclusion Criteria:
• • 1. Participants with concomitant other malignant tumors;
• • 2. Participants with missing baseline clinical data;
• • 3. Participants with severe underlying pulmonary diseases (such as bronchiectasis, bronchial asthma, or COPD), or those with a history of occupational or environmental exposure to dust, mines, or asbestos;
• • 4. Participants who are uncooperative or refuse to participate in the clinical trial later on.